Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOXIRI+Bev vs FOLFOXIRI+Bev in mCRC (QUATTRO-II)
NCT04097444Phase 2Unknown
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Primary completion
- Aug 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in metastatic colorectal cancer (mCRC), sponsored by Chugai Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04097444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097444.